Frazier Life Sciences Secures $630M for Evergreen Public Fund in Oversubscribed Fundraise
Slice of Healthcare Team
Oct 10, 2024
Key Highlights
- Frazier Life Sciences secures over $630 million in capital commitments for its Public Fund.
- Public Fund total now reaches approximately $1.7 billion under the leadership of FLS executives.
- The fund focuses on small- and mid-cap public biotech companies and later stage private investments.
- Major portfolio successes include the acquisitions of Sierra Oncology, Chinook Therapeutics, and Alpine Immune Sciences.
- FLS has overseen over 50 FDA approvals since 2010 across various portfolio companies.
Source: Business Wire
Notable Quotes
“ We’re pleased by the strong growth and meaningful milestones we’ve seen from many companies in our portfolio within the Fund’s first three years. ”
Albert Cha, Managing Partner at Frazier Life Sciences
“ Since 2010, FLS companies have received FDA approval for over 50 new therapeutics. ”
Jamie Brush, General Partner and Portfolio Manager at Frazier Life Sciences
